Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically or cytologically confirmed malignant pleural, peritoneal, or tunica vaginalis mesothelioma * Epithelial, sarcomatoid, or mixed subtype * International Mesothelioma Interest Group stage II-IV disease (for patients with pleural mesothelioma) * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR \> 10 mm by spiral CT scan * Pleural effusion and ascites are not considered measurable lesions * Disease not amenable to curative surgery * No known brain metastases * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 OR Karnofsky PS 70-100% * Life expectancy \> 3 months * White blood cell (WBC) ≥ 3,000/mm³ * Absolute neutrophil count ≥ 1,500/mm³ * Hemoglobin ≥ 8 g/dL * Platelets ≥ 100,000/mm³ * Total bilirubin normal * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal(ULN) * Creatinine normal OR creatinine clearance \> 60 mL/min * Fertile patients must use effective contraception * Not pregnant or nursing * Negative pregnancy test * No history of allergic reactions to compounds of similar chemical or biologic composition to AZD2171 * Mean corrected QT interval (QTc) ≤ 500 msec (with Bazett's correction) by EKG * No history of long QT syndrome * Proteinuria ≤ 1+ on two consecutive dipsticks taken ≥ 1 week apart * No other concurrent malignancy * No New York Heart Association class III or IV cardiac disease * No uncontroll…